troglitazone has been researched along with Benign Neoplasms, Brain in 4 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | 5.34 | The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| "Gliomas are the most common primary tumors of the central nervous system, with glioblastomas as the most malignant entity." | 1.34 | The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. ( Blümcke, I; Buslei, R; Coras, R; Eyüpoglu, IY; Hahnen, E; Hauke, J; Hölsken, A; Reichel, M; Seufert, S; Siebzehnrübl, FA; Tränkle, C, 2007) |
| "However, its expression in brain tumors has not been studied." | 1.31 | Expression of PPARgamma and its ligand-dependent growth inhibition in human brain tumor cell lines. ( Fujieda, M; Kato, M; Nagaya, T; Saito, K; Seo, H; Yoshida, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yao, CJ | 1 |
| Lai, GM | 1 |
| Chan, CF | 1 |
| Cheng, AL | 1 |
| Yang, YY | 1 |
| Chuang, SE | 1 |
| Spagnolo, A | 1 |
| Grant, EN | 1 |
| Glick, R | 1 |
| Lichtor, T | 1 |
| Feinstein, DL | 1 |
| Coras, R | 1 |
| Hölsken, A | 1 |
| Seufert, S | 1 |
| Hauke, J | 1 |
| Eyüpoglu, IY | 1 |
| Reichel, M | 1 |
| Tränkle, C | 1 |
| Siebzehnrübl, FA | 1 |
| Buslei, R | 1 |
| Blümcke, I | 1 |
| Hahnen, E | 1 |
| Kato, M | 1 |
| Nagaya, T | 1 |
| Fujieda, M | 1 |
| Saito, K | 1 |
| Yoshida, J | 1 |
| Seo, H | 1 |
4 other studies available for troglitazone and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Survival; Chromans; Cyclin A; | 2006 |
Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Surv | 2007 |
The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion.
Topics: Animals; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Chromans; DNA Primers; Dow | 2007 |
Expression of PPARgamma and its ligand-dependent growth inhibition in human brain tumor cell lines.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Blotting, Northern; Brain Neoplasms; Cell Division; C | 2002 |